NEW YORK (GenomeWeb News) – Epigenomics and Japanese firm Sysmex today said that they have entered into a research and development collaboration aimed at developing a molecular diagnostics assay for cancer based on an Epigenomics biomarker.
The companies will evaluate the suitability of Sysmex's molecular diagnostics instrumentation for detecting DNA methylation cancer biomarkers in blood. Sysmex will use Epigenomics' mSEPT9 Methylation Detection Assay as a benchmark for development of its assay. Sysmex's plan is to develop and sell in Japan a blood test for early detection of colorectal cancer based on Epigenomics' mSEPT9 biomarker.
The firms also said that they have entered into negotiations for Sysmex to take a non-exclusive license to mSEPT9.
Sysmex will have access to Epigenomics' technologies through R&D licenses and technology transfer. It also will receive R&D support from Berlin-based Epigenomics. In return, Epigenomics will receive license fees, R&D funding, and reimbursements. It also will sell its mSEPT9 research-use only assay to Sysmex.
"With Sysmex we expect to create a route to the attractive Japanese market for our early cancer detection franchise," said Epigenomics CEO Geert Nygaard in a statement.